Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 8/20 | 0.43 |
| ▸ | BCL2 | P10415 | 3/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.40 |
| ▸ | ITGAV | P06756 | 4/20 | 0.40 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 3/20 | 0.39 |
| ▸ | PPARD | Q03181 | 2/20 | 0.39 |
| ▸ | PPARA | Q07869 | 2/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2002556 | 0.86 | PPARG (0.47) | MCL1ITGB3ITGAVPPARGPPARD | |
| SCHEMBL2006435 | 0.81 | MCL1 (0.45) | MCL1BCL2PPARGPPARDPPARA | |
| SCHEMBL9979614 | 0.78 | MCL1 (0.51) | MCL1BCL2PPARGPPARDPPARA | |
| SCHEMBL4464391 | 0.76 | PPARG (0.50) | MCL1BCL2ITGB3ITGAVPPARG | |
| SCHEMBL12568445 | 0.73 | ITGB3 (0.45) | MCL1BCL2ITGB3ITGAVITGB5 | |
| SCHEMBL29138523 | 0.72 | MTNR1A (0.56) | PDE4BPDE4DMTNR1AMTNR1BMAPT | |
| SCHEMBL20037218 | 0.69 | TDP1 (0.53) | PDE4BPDE4DMAPTKMT2A | |
| SCHEMBL4234775 | 0.69 | PPARG (0.55) | MCL1ITGB3ITGAVITGB5PPARG | |
| SCHEMBL12568428 | 0.69 | PPARG (0.44) | MCL1BCL2ITGB3ITGAVITGB5 | |
| SCHEMBL2002557 | 0.69 | PPARD (0.56) | PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964622-B2 | Indole acetic acid derivatives and their use as pharmaceutical agents | BAYER HEALTHCARE LLC (US) | 2011-06-21 | — | — | US | disclosed |
| US-20090298854-A1 | Indole acetic acid derivatives and their use as pharmaceutical agents | MA XIN | 2009-12-03 | — | — | US | disclosed |
| US-7592361-B2 | (5-{3-[4-(4,5,6,7-tetrahydro-benzooxazol-2-yl)-phenoxy]-propoxy}-indol-1-yl)-acetic acid; diabetes, obesity, hyperlipidemia, and atherosclerotic disease | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-20060264486-A1 | Indole acetic acid derivatives and their use as pharmaceutical agents | BAYER HEALTHCARE LLC | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298854-A1 | Indole acetic acid derivatives and their use as pharmaceutical agents | IDO1, IDO2, AADAT | MCL1 2673/4885BCL2 2728/4885ITGB3 4684/4885 |
| US-20060264486-A1 | Indole acetic acid derivatives and their use as pharmaceutical agents | IDO1, IDO2, AADAT | MCL1 2673/4885BCL2 2728/4885ITGB3 4684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.